Some compounds are discussed as GLP-1 receptor agonists, while others are discussed as dual or multi-receptor research compounds
Mentz et al., 2016
People with certain conditions, like a history of thyroid issues or pancreatitis, may need to avoid it
Important nteractions one should check out for: Corticosteroids additive hyperglycemic Thiazide diuretics additive glucose elevation Non-selective beta-blockers (e.g., propranolol) can mask hypoglycemia symptoms in insulin/sulfonylurea users CYP1A2 modulators (e.g., smoking cessation during admission) can raise olanzapine levels unexpectedly QT-prolonging co-prescriptions (fluoroquinolones, macrolides, ondansetron) additive QTc risk Anticholinergic burden can worsen diabetic gastroparesis 3.Interventions Baseline and periodic fasting glucose, lipid panel, weight/BMI Track HbA1c trend from olanzapine initiation Discuss risk-benefit of lower metabolic-risk alternatives (e.g., aripiprazole) where clinically appropriate Don't dismiss deteriorating glucose control as "just illness stress" screen actively This is the kind of case that reminds us why the pharmacist's seat at the ward round table matters catching interactions that aren't always obvious on a first glimpse of a prescription
The FDA has issued warnings that compounded medications are not assessed for quality, safety, or efficacy (Forbes Health)
What is the recommended dosage of Mounjaro
